20/20 Biolabs, Inc. Common Stock Market Cap ($2.17 Million)
Market Cap & Net Worth: 20/20 Biolabs, Inc. Common Stock (AIDX)
20/20 Biolabs, Inc. Common Stock market cap. 20/20 Biolabs, Inc. Common Stock (NASDAQ:AIDX) has a market capitalization of $2.17 Million ($2.17 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29959 globally and #6119 in its home market, demonstrating a -16.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 20/20 Biolabs, Inc. Common Stock's stock price $0.21 by its total outstanding shares 10347232 (10.35 Million). Also see AIDX operating cash flow for how efficiently the company converts equity into cash flow.
20/20 Biolabs, Inc. Common Stock Market Cap History (2026–2026)
20/20 Biolabs, Inc. Common Stock market cap history from 2026 to 2026. Data shows growth from $2.17 Million to $2.17 Million (0.00% CAGR). Check AIDX share price today for real-time trading data and today's change.
20/20 Biolabs, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 20/20 Biolabs, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore AIDX year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AIDX by Market Capitalization
Companies near 20/20 Biolabs, Inc. Common Stock in the global market cap rankings as of November 3, 2026. Also see AIDX total assets for a full breakdown of the balance sheet.
Key companies related to 20/20 Biolabs, Inc. Common Stock by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $184.67 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #215 globally with a market cap of $111.95 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #225 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $184.67 Billion | $106.20 |
| #215 | Stryker Corporation | NYSE:SYK | $111.95 Billion | $291.86 |
| #225 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $96.54 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of 20/20 Biolabs, Inc. Common Stock (2026–2026)
Market capitalization of 20/20 Biolabs, Inc. Common Stock from 2026 to today. Between 2026 and today, 20/20 Biolabs, Inc. Common Stock's market cap moved from $2.17 Million to $ 2.17 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.17 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of 20/20 Biolabs, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.17 Million USD |
| MoneyControl | $2.17 Million USD |
| MarketWatch | $2.17 Million USD |
| marketcap.company | $2.17 Million USD |
| Reuters | $2.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more